Fulminant type 1 diabetic ketoacidosis due to serplulimab
10.3760/cma.j.cn114015-20240410-00240
- VernacularTitle:斯鲁利单抗致暴发性1型糖尿病酮症酸中毒
- Author:
Xu DENG
1
;
Yan DAI
1
;
Tingting LI
1
;
Yun GAO
1
;
Tiantian DAI
1
;
Mingqin GE
1
;
Shilong WANG
1
Author Information
1. 临沂市中心医院内分泌科，临沂 276400
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Diabetes mellitus, type 1;
Diabetic ketoacidosis;
Serplulimab
- From:
Adverse Drug Reactions Journal
2025;27(7):440-442
- CountryChina
- Language:Chinese
-
Abstract:
A 57-year-old female patient with small cell lung cancer was treated with serplulimab (100 mg by intravenous infusion on the first day, 21 days as a cycle). After the 10th cycle of treatment, the patient suddenly presented drowsiness, shortness of breath, dry mouth, nausea, vomiting, fatigue and other symptoms. Laboratory tests showed fasting blood glucose 38.9 mmol/L, glycosylated hemoglobin 7.9%, serum C peptide 0.2 μg/L, pH value 7.05, anion gap 31 mmol/L, anti-islet cell antibody 36 kU/L, anti-glutamic acid decarboxylase antibody 131 kU/L, urine ketone body (+++). The patient was diagnosed with fulminant type 1 diabetic ketoacidosis, which was considered to be related to serplulimab. The drug was stopped, and insulin, rehydration, correction of acid-base imbalance, and other treatments were given. After 3 days, the patient′s consciousness returned to normal. After 12 days, her breathing was stable, dry mouth, nausea, vomiting and other symptoms were relieved. Laboratory tests showed random blood glucose 13.6 mmol/L, pH value 7.44, anion gap 6 mmol/L, and urine ketone body negative. After 26 days, her random blood glucose was controlled at 10.0-12.0 mmol/L.
